Reply to “Metformin as a booster or obstacle of immunotherapy in patients with non–small cell lung cancer and diabetes mellitus”-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reply to “Metformin as a booster or obstacle of immunotherapy in patients with non–small cell lung cancer and diabetes mellitus”

Published:2023-11-21 Issue:2 Volume:130 Page:324-324
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Leshem Yasmin¹²^ORCID,Dolev Yardenna¹,Siegelmann‐Danieli Nava³⁴,Sharman Moser Sarah³,BPharm Lior Apter³⁵,Chodick Gabriel³⁴,Nikolaevski‐Berlin Alla¹,Shamai Sivan¹,Merimsky Ofer¹,Wolf Ido¹⁴

Affiliation:

1. Oncology Division Tel Aviv Sourasky Medical Center Tel Aviv Israel

2. Department of Immunology Weizmann Institute of Science Rehovot Israel

3. Maccabi Institute for Research and Innovation (Maccabitech) Maccabi Healthcare Services Tel Aviv Israel

4. Sackler School of Medicine Tel Aviv University Tel Aviv Israel

5. Department of Health Systems Management Ben‐Gurion University of the Negev Beer‐Sheva Israel

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference6 articles.

1. Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer

2. Comparison of Propensity Score Methods and Covariate Adjustment

3. Propensity score methods in observational research: brief review and guide for authors

4. Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP